UBS Downgrades AstraZeneca (AZN) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks hit by tech slide; yen flails at intervention zone
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
AstraZeneca (AZN) Misses Q3 EPS by 6c
October 31, 2013 8:46 AM EDTAstraZeneca (NYSE: AZN) reported Q3 EPS of $1.21, $0.06 worse than the analyst estimate of $1.27. Revenue for the quarter came in at $6.25 billion versus the consensus estimate of $6.45 billion.
For earnings history and earnings-related data on AstraZeneca (AZN) click here.... More
AstraZeneca (AZN) Promotes Dunoyer to CFO; Remains on SET
October 31, 2013 8:44 AM EDTAstraZeneca (NYSE: AZN) announced that Marc Dunoyer has been appointed Chief Financial Officer and will join the company Board as an Executive Director. He succeeds Simon Lowth who leaves AstraZeneca today, as previously announced. Marc Dunoyer's appointment takes effect on 1 November 2013. He will report to Chief Executive Officer, Pascal Soriot and remain a member of the Senior Executive Team (SET).
Marc Dunoyer, currently Executive Vice President, Global Portfolio & Product Strategy, joined AstraZeneca from... More
